A bipartisan group of 81 U.S. lawmakers has formally urged the Food and Drug Administration (FDA) to intensify efforts against compounded and counterfeit GLP-1 weight-loss drugs, citing serious safety concerns. The lawmakers sent a letter requesting an enforcement update by July 30, emphasizing the risks associated with fake and copycat medications in this category. The crackdown targets illegal and counterfeit GLP-1 drugs, which have been linked to a surge in safety issues and illegal imports, including from China. The pharmaceutical companies Hims & Hers Health Inc. ($HIMS), Eli Lilly ($LLY), and Novo Nordisk ($NVO) are notably mentioned in relation to the issue. The news has impacted $HIMS stock, which experienced a price drop amid the regulatory pressure. Lawmakers are pressing the FDA to take stronger action to protect patients from these unsafe weight-loss drugs.